Virological response to peramivir treatment in adults hospitalised for influenza-associated lower respiratory tract infections.
An open-label trial on intravenous peramivir was conducted among adult patients hospitalised for influenza-associated lower respiratory tract complications (LRTCs). Virus culture and quantitative reverse transcription PCR (qRT-PCR) were performed serially until Day 10. Peramivir treatment was associated with viral RNA decline as well as culture and RNA negativity, which occurred at rates comparable with those of oseltamivir: by Day 5, viral load decline -2.5 log10 copies/mL [βinteraction -0.071, standard error (SE) 0.121, 95% confidence interval (CI) -0.309 to 0.167]; culture-negative, 94% (vs. 95%); and RNA-negative, 44% (vs. 36%). Extended treatment of >5 days was required in 69% of cases because of slow clinical resolution and viral clearance in LRTCs. Peramivir was well tolerated. These data are useful for future trial design in this unique population.
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: leelsn@cuhk.edu.hk.
N
N
Lee
Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; Department of Microbiology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.
P K S
PK
Chan
Alice Lee Centre for Nursing Studies, National University of Singapore, Singapore.
W W S
WW
Tam
Department of Microbiology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.
M C W
MC
Chan
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.
G C Y
GC
Lui
Department of Microbiology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.
A K
AK
Kwok
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.
F W S
FW
Ko
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.
S S S
SS
Ng
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.
I M H
IM
Yung
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.
R Y K
RY
Wong
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: dschui@cuhk.edu.hk.
D S C
DS
Hui
D000146:Acids, Carbocyclic; D061605:Administration, Intravenous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001996:Bronchopneumonia / Q000188:drug therapy*; D003517:Cyclopentanes / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006146:Guanidines / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007251:Influenza, Human / Q000150:complications*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000302:isolation & purification; D060888:Real-Time Polymerase Chain Reaction; D016896:Treatment Outcome; D019562:Viral Load; D014776:Virus Cultivation; D055815:Young Adult
D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D006146:Guanidines; D012367:RNA, Viral; C414210:peramivir
Influenza; Lower respiratory tract complications; Peramivir